Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs

Kesharwani, Roohi; Jaiswal, Pankaj Kumar; Patel, Dilip Kumar; Yadav, Pankaj

doi:10.1007/s44174-022-00041-0

Cited by 16 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLNs, a novel method of administering colloidal drugs, consist of physiological fluids that are solid at room temperature as well as body temperature ( 63 ). These particles range in size from 50 nm to 1,000 nm.…”

Section: Classification Of Lbnpsmentioning

confidence: 99%

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Waheed,

Ali,

Tabassum

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cancer is a severe disease that results in death in all countries of the world. A nano-based drug delivery approach is the best alternative, directly targeting cancer tumor cells with improved drug cellular uptake. Different types of nanoparticle-based drug carriers are advanced for the treatment of cancer, and to increase the therapeutic effectiveness and safety of cancer therapy, many substances have been looked into as drug carriers. Lipid-based nanoparticles (LBNPs) have significantly attracted interest recently. These natural biomolecules that alternate to other polymers are frequently recycled in medicine due to their amphipathic properties. Lipid nanoparticles typically provide a variety of benefits, including biocompatibility and biodegradability. This review covers different classes of LBNPs, including their characterization and different synthesis technologies. This review discusses the most significant advancements in lipid nanoparticle technology and their use in medicine administration. Moreover, the review also emphasized the applications of lipid nanoparticles that are used in different cancer treatment types.

show abstract

Section: Classification Of Lbnpsmentioning

confidence: 99%

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Waheed,

Ali,

Tabassum

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Moreover, a decline in biotransformation capacity is observed with age in humans [4]. Alternative methods of bioavailability enhancement include creating lipid-based drug delivery systems [5], obtaining a long-term stable amorphous solid dispersion of the drug with an excipient, prebiotic, or other drug [6], and forming a drug inclusion complex with cyclodextrin (CD) [7]. These methods do not involve the chemical derivatisation of an active substance to form a prodrug and do not rely on human biotransformation; therefore, in this approach, a novel delivery system of native ceftobiprole with selected CDs was proposed on the basis of theoretical methods.…”

Section: Peer Reviewmentioning

confidence: 99%

Investigation of the Affinity of Ceftobiprole for Selected Cyclodextrins Using Molecular Dynamics Simulations and HPLC

Boczar,

Michalska

2023

IJMS

View full text Add to dashboard Cite

This paper presents the theoretical calculations of the inclusion complex formation between native ceftobiprole, a promising antibiotic from the cephalosporin group, and selected cyclodextrins (CDs) approved by the European Medicines Agency. Ceftobiprole was studied in three protonation states predicted from pKa calculations, along with three selected CDs in a stoichiometric ratio of 1:1. It was introduced into the CD cavity in two opposite directions, resulting in 18 possible combinations. Docking studies determined the initial structures of the complexes, which then served as starting structures for molecular dynamics simulations. The analysis of the obtained trajectories included the spatial arrangement of ceftobiprole and CD, the hydrogen bonds forming between them, and the Gibbs free energy (ΔG) of the complex formation, which was calculated using the Generalised Born Surface Area (GBSA) equation. Among them, a complex of sulfobutyl ether- (SBE-) β-CD with protonated ceftobiprole turned out to be the most stable (ΔG = −12.62 kcal/mol = −52.80 kJ/mol). Then, experimental studies showed changes in the physiochemical properties of the ceftobiprole in the presence of the CDs, thus confirming the validity of the theoretical results. High-performance liquid chromatography analysis showed that the addition of 10 mM SBE-β-CD to a 1 mg/mL solution of ceftobiprole in 0.1 M of HCl increased the solubility 1.5-fold and decreased the degradation rate constant 2.5-fold.

show abstract

“…Oral lipid-based techniques include things like straightforward lipid solutions including self-emulsifying drug delivery systems. 57 Table 2 provides details on current patent filings for solid lipid NP with SLN.…”

Section: Hemolytic Toxicitymentioning

confidence: 99%

A Birds Eye View on Solid Lipid Nanoparticles and Applications in Drug Delivery System

Pagar,

Pawar

2023

IJDDT

View full text Add to dashboard Cite

Solid lipid nanoparticles (SLN) might provide fresh opportunities for treating challenging ailments. The SLN were established in the 1990s to replace emulsions and liposomes, in addition to polymeric nanoparticles (NP) as carrier systems. SLN are wet cohesive dispersions with solid biodegradable lipids as their matrices. Drug delivery techniques called SLN use both liquid and solid lipids as their primary matrices. It was demonstrated that SLNs have several benefits over conventional carriers for drug therapy, a longer half-life, tissue-targeted administration, higher permeability, enhanced bioavailability, enhanced solubility, as well as the capacity to enhance storage stability. Because of their exclusive size-dependent characteristics as well as their capability towards incorporating drugs, SLN’s currently a possibility towards designing promising pharmacological prototypes for drug transport as well as targeting. The objective of tailored as well as monitored drug delivery is now unsettling researchers’ interests across the globe, and can be accomplished through the support of SLNs. The present investigation emphasizes SLNs’ numerous characteristics as well as development and evaluation processes, formulation factors, delivery routes, surface changes, toxicity, and biomedical applications

show abstract

Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs

Cited by 16 publications

References 94 publications

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Investigation of the Affinity of Ceftobiprole for Selected Cyclodextrins Using Molecular Dynamics Simulations and HPLC

A Birds Eye View on Solid Lipid Nanoparticles and Applications in Drug Delivery System

Contact Info

Product

Resources

About